Arterial calcification develops gradually and often without symptoms. Calcium deposits accumulate within the arterial wall over years, contributing to stiffness and reduced vascular elasticity. Many individuals remain unaware of these structural changes until they are detected incidentally through imaging or until cardiovascular disease becomes clinically evident.
Vascular calcification is not a random event. It is associated with ageing, diabetes, chronic kidney disease, hypertension, chronic inflammation, and disturbances in mineral metabolism. Rather than being a simple passive process, calcification is now understood as an actively regulated biological phenomenon.
Vitamin K exists in multiple forms. Vitamin K1 primarily supports blood clotting. Vitamin K2 (menaquinone), particularly in its MK-7 form, plays a role in activating vitamin K–dependent proteins such as Matrix Gla Protein (MGP), which helps inhibit vascular calcification, and osteocalcin, which supports bone mineralisation.
When Vitamin K2–dependent proteins are insufficiently activated, calcium regulation may become less efficient. This has led researchers to explore whether Vitamin K2 intake influences cardiovascular risk.
The Rotterdam Study, a large prospective cohort study, reported that higher dietary menaquinone intake was associated with reduced coronary heart disease risk and lower cardiovascular mortality (Geleijnse et al., 2004).
It is important to emphasise that observational studies demonstrate association, not causation. A randomised controlled trial later showed that long-term MK-7 supplementation improved arterial stiffness parameters in postmenopausal women (Knapen et al., 2015).
While promising, this does not establish Vitamin K2 as a preventive or curative therapy for cardiovascular disease. Arterial health depends on multiple interacting factors.
In chronic kidney disease, disturbances in calcium–phosphate balance significantly accelerate vascular calcification. The KDIGO clinical practice guidelines describe how impaired mineral regulation contributes to arterial stiffening in CKD (KDIGO, 2009).
This reinforces a key principle: calcium deposition is rarely caused by a single nutrient imbalance. It reflects broader metabolic dysregulation.
Traditional systems of medicine have long described the importance of proper tissue transformation and metabolic balance. Although terminology differs, modern cardiovascular research similarly recognises that endothelial function, inflammation, oxidative stress, and mineral handling collectively determine arterial resilience.
When calcium supplementation, Vitamin D intake, or cardiometabolic risk factors are present, individualised assessment becomes important.
If there is concern about arterial stiffness, lipid imbalance, or metabolic risk, a comprehensive cardiovascular and metabolic evaluation may be appropriate.
This allows evaluation of blood pressure, lipid profile, glucose status, kidney function, inflammatory markers, and overall risk burden before making decisions regarding supplementation.
Similarly, individuals currently taking calcium or Vitamin D supplements may benefit from a structured clinical consultation for cardiovascular risk assessment.
Vitamin K2 is found in fermented foods and certain animal-derived products, though intake varies widely by dietary pattern. Supplementation may be considered in select populations, but current clinical guidelines do not recommend routine Vitamin K2 supplementation for cardiovascular prevention.
Evidence-based cardiovascular risk reduction remains centred on:
• Blood pressure control
• Lipid optimisation
• Glycaemic regulation
• Physical activity
• Smoking cessation
• Weight management
Nutrients function within this broader framework they do not replace it.
Arterial calcification often progresses silently. Vitamin K2 plays a biologically plausible role in calcium regulation, and research suggests potential associations with vascular health. However, it should be understood as one component within a complex metabolic system.
Structured evaluation, early risk identification, and comprehensive lifestyle and medical management remain the most reliable strategies for protecting long-term cardiovascular health.
Geleijnse JM et al. (2004). Dietary intake of menaquinone is associated with reduced risk of coronary heart disease. [LINK]
Knapen MHJ et al. (2015). Menaquinone-7 supplementation improves arterial stiffness in healthy postmenopausal women. Thrombosis and Haemostasis. [LINK]
KDIGO Clinical Practice Guideline for CKD–Mineral and Bone Disorder. (2009). [LINK]
This article is intended for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Arterial calcification and cardiovascular disease are complex medical conditions requiring individualised evaluation. Vitamin supplementation should be undertaken only under the guidance of a qualified healthcare professional, particularly in individuals with kidney disease, cardiovascular disease, or those taking anticoagulant medications. Integrative approaches should complement, not replace, evidence-based medical care.
